A study has shown that adiponectin may induce an anti-angiogenic and metastatic inhibitory capacity in RCC cells by AMPK pathway activation and decreased secretion of MMP2, MMP-9, and VEGF [167]. Here, ADIPOQ is linked to renal cell carcinoma.